Quarterly report · Q3
4583.TEDINET S100S992
Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥524m | 2023-01-01 → 2023-09-30 | Standalone | Net sales |
| Revenue | ¥631m | 2022-01-01 → 2022-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥434m | 2022-01-01 → 2022-09-30 | Standalone | Net sales |
| Operating income | −¥905m | 2023-01-01 → 2023-09-30 | Standalone | Operating income |
| Operating income | −¥1.0bn | 2022-01-01 → 2022-09-30 | Standalone | Operating income |
| Ordinary income | −¥916m | 2023-01-01 → 2023-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.0bn | 2022-01-01 → 2022-09-30 | Standalone | Ordinary income |
| Profit before tax | −¥915m | 2023-01-01 → 2023-09-30 | Standalone | Income before income taxes |
| Profit before tax | −¥1.0bn | 2022-01-01 → 2022-09-30 | Standalone | Income before income taxes |
| Net income | −¥918m | 2023-01-01 → 2023-09-30 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.0bn | 2022-01-01 → 2022-09-30 | Standalone | Profit loss |
| Total assets | ¥1.8bn | at 2023-09-30 | Standalone | Assets |
| Total assets | ¥2.2bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥2.1bn | at 2022-09-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥542m | at 2023-09-30 | Standalone | Liabilities |
| Total liabilities | ¥425m | at 2022-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.2bn | at 2023-09-30 | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.7bn | at 2022-09-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2023-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2022-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-18.82 | 2023-01-01 → 2023-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.15 | 2023-07-01 → 2023-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-28.26 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-23.87 | 2022-01-01 → 2022-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.8 | 2022-07-01 → 2022-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 67.8% | at 2023-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.4% | at 2022-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 50,571,400 | at 2023-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,423,500 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 45,979,100 | at 2022-09-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-09-30 | −¥409m |
| jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2023-01-01 → 2023-09-30 | −¥803m |
| jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥524m |
| jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥524m |
| jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥307m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-09-30 | ¥524m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-09-30 | ¥524m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-09-30 | −¥496m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-09-30 | −¥358m |
| jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2022-01-01 → 2022-09-30 | −¥916m |
| jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥434m |
| jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥434m |
| jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥235m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-09-30 | ¥434m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-09-30 | ¥434m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-09-30 | −¥681m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 329
| Item | Context | Value | Unit |
|---|---|---|---|
| Profit loss | CurrentYTDDuration_NonConsolidatedMember | -918465000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 433694000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 433694000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember | 433694000 | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoverySupportReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 433694000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 433694000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember | 433694000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | -916417000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 234990000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | -681426000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | -357902000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember | -1039329000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 524023000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 524023000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember | 524023000 | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoverySupportReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 524023000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 524023000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember | 524023000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | -803247000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 307091000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | -496156000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | -409157000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember | -905313000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-11-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第20期第３四半期（自 2023年７月１日 至 2023年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社カイオム・バイオサイエンス | |
| Company name in english cover page | FilingDateInstant | Chiome Bioscience Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 小林 茂 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都渋谷区本町三丁目12番１号 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |